Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- None.
- None.
The advancement of SAR443579 / IPH6101 to Phase 2 by Innate Pharma and the triggering of a €4 million milestone payment from Sanofi are of significant interest to investors and stakeholders in the biopharmaceutical sector. The transition from early-stage clinical trials to Phase 2 indicates a certain level of confidence in the potential efficacy and safety of the treatment, suggesting that the companies are one step closer to potentially bringing a new therapy to market.
Financially, milestone payments such as the one received by Innate Pharma are critical components of partnership agreements in the drug development industry. They provide non-dilutive funding which can support ongoing research and development costs and are often seen as positive indicators of a drug candidate's progress. However, investors should be aware that the drug is still in the trial phase and commercialization is contingent on successful completion of all clinical trial phases and regulatory approval processes. Moreover, the specific amount of the milestone payment suggests a modest financial impact relative to the overall cost of drug development.
The progression of the NK cell engager SAR443579 / IPH6101 to Phase 2 for the treatment of blood cancers represents a potential breakthrough in oncology, particularly for conditions with high unmet medical needs such as relapsed or refractory acute myeloid leukemia (R/R AML). NK cell engagers are a novel class of immunotherapies designed to direct natural killer (NK) cells to target and kill cancer cells, an approach that could complement or offer an alternative to existing treatments such as chemotherapy and CAR-T therapies.
The fact that SAR443579 has received FDA Fast Track Designation is noteworthy, as this status is granted to expedite the development of drugs which treat serious conditions and fill an unmet medical need. This designation can lead to an expedited review process, potentially bringing the drug to market more quickly if clinical trials are successful. However, while promising, the efficacy and safety profile of SAR443579 will be further scrutinized in this next phase of the trial and the outcomes of Phase 2 will be pivotal in determining the drug's future.
-
Partner Sanofi advances
SAR443579 / IPH6101, ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers -
Dosing of the first patient in the dose expansion part of the trial triggers a
€4m milestone payment to Innate
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of
“The progression of
Under the terms of the 2016 research collaboration with Sanofi, the progression to the dose expansion part of the trial has triggered a milestone payment from Sanofi to Innate of
“Our goal is to continue to develop the best and most impactful treatments for patients with cancer,” said Peter Adamson, Global Development Head, Oncology, Sanofi.“We are encouraged by our progress in this study for patients with AML, and look forward to sharing results in the future as data continues to emerge.”
More information about the Phase 1/2 trial can be found on clinicaltrials.gov.
About ANKET®
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.
About the Innate-Sanofi research collaboration and licensing agreements
The Company has a research collaboration and license agreement with Sanofi to apply Innate’s proprietary technology to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells.
Under the terms of the 2016 research collaboration and license agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration, which includes
As part of the license agreement entered in December 2022, Sanofi licensed IPH62 and IPH67 and has the option for one additional target. Under the terms of the 2022 agreement, Innate Pharma is eligible to up to
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on X and LinkedIn.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240414715190/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
